Abstracts tagged "rheumatoid arthritis"

Abstract Number: 2047 • ACR Convergence 2025
Trends in Lung Transplant Listing Outcomes in Connective Tissue Disease associated Interstitial Lung Disease (CTD-ILD) Across Two Decades
Sambhawana Bhandari¹, Derek E. Byers¹ and Deepali Sen², ¹Washington University in St. Louis School of Medicine, St. Louis, ²Washington University in St Louis, Chesterfield, MO
Background/Purpose: Lung transplantation represents a potential life-extending therapy for patients with advanced CTD-ILD. This study aims to characterize lung transplant listing outcomes among CTD-ILD patients…
Abstract Number: 1927 • ACR Convergence 2025
Development of the PREVAIL model of care: Optimizing feasibility and acceptability for trial implementation
Louise Thoma¹, Joel Thompson², Jason Sharpe³, Beth Jonas⁴, Patti Katz⁵ and Kelli Allen⁶, ¹University of North Carolina, Chapel Hill, NC, ²University of North Carolina at Chapel Hill, Cary, NC, ³Flatiron Health, Durham, NC, ⁴University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁵UCSF, San Rafael, CA, ⁶University of North Carolina, Durham, NC
Background/Purpose: Exercise guidance and referral to physical therapy are not consistently delivered when appropriate in rheumatology care for adults with rheumatoid arthritis (RA). The PREVAIL…
Abstract Number: 1749 • ACR Convergence 2025
External validation of a combined clinical and genetic risk score for the identification of interstitial lung disease in rheumatoid arthritis
Mikael Brink¹, Austin Wheeler², Bryant England² and Solbritt Rantapaa-Dahlqvist³, ¹Umeå Universitet, Umeå, Sweden, ²University of Nebraska Medical Center, Omaha, NE, ³Umeå University, Umea, Sweden
Background/Purpose: RA-associated interstitial lung disease (RA-ILD) causes substantial morbidity and mortality in RA. Despite this, a limited number of clinical and genetic risk factors have…
Abstract Number: 1676 • ACR Convergence 2025
Long-Term Safety and Efficacy of Upadacitinib or Adalimumab in Patients With Rheumatoid Arthritis: 7-Year Data From the SELECT-COMPARE Study
Roy Fleischmann¹, Jerzy Swierkot², Patrick Durez³, Louis Bessette⁴, Xianwei Bu⁵, Irina Fish⁵, Andrew Gara⁵, Diane Caballero⁵, Charles Peterfy, MD, PhD⁶, Yoshiya Tanaka⁷ and Eduardo Mysler⁵, ¹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ²Wroclaw Medical University, Department of Rheumatology and Internal Medicine, Wroclaw, Poland, ³Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCLouvain) – Institut de Recherche Expérimentale et Clinique (IREC), Rheumatology, Brussels, Belgium, ⁴Centre de l'Ostéoporose et de Rhumatologie de Québec, Quebec, QC, Canada, ⁵AbbVie Inc., North Chicago, ⁶Spire Sciences, Inc., Boca Raton, FL, ⁷University of Occupational and Environmental Health, Japan, Kitakyushu, Japan
Background/Purpose: We assessed the safety and efficacy of UPA versus ADA from SELECT-COMPARE through 7-years.Methods: Patients with RA and an inadequate response to MTX were…
Abstract Number: 1372 • ACR Convergence 2025
Treatment Patterns and Outcomes After Janus Kinase Inhibitor Discontinuation in Rheumatoid Arthritis: A Real-World Cohort Study
Sungwon Ko¹, Young-Eun Kim¹, Soo Min Ahn¹, Ji Seon Oh¹, Yong-Gil Kim¹, Chang-Keun Lee², Bin Yoo¹ and Seokchan Hong¹, ¹Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea, Seoul, Republic of Korea, ²Department of Rheumatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Seoul, Republic of Korea
Background/Purpose: Janus kinase (JAK) inhibitors are recommended for patients with rheumatoid arthritis (RA) who have an inadequate response to conventional synthetic or biologic disease-modifying antirheumatic…
Abstract Number: 1354 • ACR Convergence 2025
Effect of Ivarmacitinib on Joint Swelling and Tenderness in Patients with Moderate-to-severe Rheumatoid Arthritis: A Post-hoc Study of a Phase III Clinical Trial
Hongtao Jin, Huifang Guo, Yuxiang Han and Meng Ding, The Second Hospital of Hebei Medical University, Shijiazhuang, China (People's Republic)
Background/Purpose: Joint swelling and tenderness are major symptoms of rheumatoid arthritis (RA). This post-hoc analysis evaluated the effect of ivarmacitinib (SHR0302), a selective Janus kinase…
Abstract Number: 1337 • ACR Convergence 2025
The Association Between Glucagon-Like Peptide-1 Receptor Agonist and Rheumatoid Arthritis: A Population-Based Case Control Study
Ariel Israel¹, Fadi Hassan², Jalal Kurtam², Jamal Awad², Eugene Merzon¹ and Mohammad Naffaa³, ¹Leumit Health Services, Tel-Aviv, Israel, ²Galilee Medical Center, Nahariya, Israel, ³The Azriel's Faculty of Medicine, Bar-Ilan University, Safed, Israel; The Rheumatology Unity, Galilee Medical Center, Naharyia, Israel
Background/Purpose: The increasing use of glucagon-like peptide-1 receptor agonists (GLP1-RAs) for diabetes mellitus (DM) and weight loss has the potential modify the risk for rheumatoid…
Abstract Number: 1321 • ACR Convergence 2025
Efficacy and safety of janus kinase inhibitors in diffuse interstitial lung disease in rheumatoid arthritis. Systematic review
Olga Compán¹, Marta Ibañez², Olga Martínez³, Carolina Cristina Chacón⁴, Ricardo López Pérez³, Borja Felices López³, Belén Miguel Ibáñez³, Laura Blanco⁴, Sergio Cimadevila Santiago³, Ana Isabel Turrión Nieves³, Manuel Cipriano Martin Martinez³, Cristina Hidalgo Calleja⁴, Carlos Montilla⁴ and Susana Gómez⁴, ¹Rheumatology Service, University Hospital of Salamanca, Carbajosa de la Sagrada, ³⁷¹⁹¹, Spain, ²Hospital Universitario de la Santa Creu i Sant Pau, Barcelona, Catalonia, Spain, ³Hospital Universitario de Salamanca, Salamanca, Castilla y Leon, Spain, ⁴Rheumatology Service, University Hospital of Salamanca, Salamanca, Castilla y Leon, Spain
Background/Purpose: Interstitial lung disease (ILD) is a relatively common serious extra-articular complication in rheumatoid arthritis (RA). Although there have been great advances, we do not…
Abstract Number: 1267 • ACR Convergence 2025
Patient Reported Outcomes Predict Subsequent Treatment Intensification Among Rheumatoid Arthritis Patients: Longitudinal PRO Measurement Using a Mobile Health App
Leah Santacroce¹, Misti Paudel² and Daniel Solomon³, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, ³Brigham and Women's Hospital, Newton, MA
Background/Purpose: Patient Reported Outcomes (PROs) collected via a mobile health application (App) can provide valuable insight into the health of patients with Rheumatoid Arthritis (RA).…
Abstract Number: 1102 • ACR Convergence 2025
Checkpoint Inhibitor Inflammatory Arthritis: Single Center Case Identification and Chart Validation.
Julia Barasch¹, Nilasha Ghosh², Deanna Jannat-Khah³, Kyle Ge⁴, Jeffrey Curtis⁵ and Anne R. Bass³, ¹NYP- Weill Cornell, New York, ²Hospital for Special Surgery, New York, NY, ³Hospital For Special Surgery, New York, NY, ⁴Hospital for Special Surgery, New York, ⁵Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL
Background/Purpose: New onset inflammatory arthritis (IA) is reported in 6% of patients who receive immune checkpoint inhibitors (ICI). We previously developed an administrative claims-based algorithm…
Abstract Number: 1027 • ACR Convergence 2025
GLP-1 Receptor Agonists to Facilitate Weight Loss and Improve Disease Activity, Pain and Function in Patients With Rheumatic and Musculoskeletal Disease: Real-World Evidence From the Rheumatology Informatics System for Effectiveness (RISE) Registry
Nick McCormick¹, Jingyi Zhang², Emily Holladay², Fenglong Xie³ and Jeffrey Curtis⁴, ¹Auburn University, Auburn, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³The University of Alabama at Birmingham, Birmingham, AL, ⁴Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL
Background/Purpose: Glucagon-like peptide-1 receptor agonists (GLP-1 RA) such as semaglutide (SEM; GLP-1) and tirzepatide (TIR; GIP/GLP-1), were initially approved for type 2 diabetes management but…
Abstract Number: 0925 • ACR Convergence 2025
Pathogenic role of SPP1+ macrophages in Rheumatoid Arthritis
Megan M. Hanlon¹, Catherine Manning¹, Kevin Wei¹, Ursula Fearon² and Ellen M. Gravallese³, ¹Brigham and Women's Hospital at Harvard Medical School, Boston, MA, ²Trinity College Dublin, Dublin, Dublin, Ireland, ³Brigham and Women's Hospital, Harvard Medical School, Chestnut Hill, MA
Background/Purpose: Synovial tissue macrophages (STMs) represent a mixed population of cells contributing to the pathogenesis of rheumatoid arthritis (RA). We identified an enrichment of Secreted…
Abstract Number: 0834 • ACR Convergence 2025
Heterogeneity in the Association of Genetic Risk for Rheumatoid Arthritis and Resultant Rheumatoid Arthritis Phenotypes
Thomas Riley¹, Austin Wheeler², Bryant England², Grant Cannon³, Brian Sauer⁴, Gary Kunkel⁵, Katherine Wysham⁶, Beth Wallace⁷, Paul Monach⁸, Andreas Reimold⁹, Gail Kerr¹⁰, Isaac Smith¹¹, John Richards¹², Iris Lee¹³, Geoffrey Thiele², Rui Xiao¹, Scott Damrauer¹⁴, Michael Levin¹⁴, Michael George¹, Ted Mikuls² and Joshua Baker¹, ¹University of Pennsylvania, Philadelphia, PA, ²University of Nebraska Medical Center, Omaha, NE, ³University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁴Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁵University of Utah and George E Wahlen VAMC, Salt Lake City, UT, ⁶VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ⁷Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, ⁸VA Boston Healthcare System, Boston, MA, ⁹Dallas VA Medical Center, Dallas, TX, ¹⁰Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ¹¹Duke University Hospital, Durham, NC, ¹²Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA, ¹³Washington University in St Louis, Saint Louis, MO, ¹⁴University of Pennsylvania / Corporal Michael J. Crescenz VAMC, Philadelphia, PA
Background/Purpose: The impact of genetic risk factors on rheumatoid arthritis (RA) phenotype is incompletely understood. Comparing individual genetic variants associated with RA susceptibility to a…
Abstract Number: 0775 • ACR Convergence 2025
Increased Circulating Microbial Small RNA tDR-1 is Associated with Decreased Progression to Future Clinical Rheumatoid Arthritis In High Risk Individuals and Reduces In Vitro Type 1 Interferon Response Gene Expression
Anastasiia Phothisane¹, Tulsi Joishy², Carolina Ramirez-Becerra¹, Zuofei Wang², Qiong Wu³, Jennifer Seifert⁴, Marie Feser⁵, Jill Norris⁶, Kristen Demoruelle⁷, LauraKay Moss⁵, Kevin Deane⁸, V. Michael Holers⁹ and Michelle Ormseth², ¹Vanderbilt University Medical Center, Nashville, TN, ²Vanderbilt University Medical Center, Nashville, ³University of Virginia, Charlottesville, VA, ⁴University of Colorado and Oklahoma Medical Research Foundation, Aurora, CO, ⁵University of Colorado Anschutz Medical Campus, Aurora, CO, ⁶Colorado School of Public Health, Denver, CO, ⁷University of Colorado Anschutz Medical Campus, Golden, CO, ⁸University of Colorado Denver Anschutz Medical Campus, Aurora, CO, ⁹University of Colorado Anschutz Medical Campus, Aurora
Background/Purpose: Microbial small RNAs (sRNAs) can regulate human genes, often with anti-inflammatory effects. We previously showed that an increased plasma concentration of a tRNA-derived RNA…
Abstract Number: 0490 • ACR Convergence 2025
Infection Risks Associated with Monotherapy and Combination Therapies Using Biological or Targeted – DMARD in RA: A Systematic Review and Network Meta-analysis
Li Liu¹, Xue-Mei Zhang¹, Zhi-Chun Gu¹ and Jia Li², ¹Ren Ji Hospital, Shanghai Jiao Tong University School Of Medicine, Pu Dong Xin Qu, Shanghai, China (People's Republic), ²Department of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China (People's Republic)
Background/Purpose: This study aimed to evaluate the infection risks in patients with rheumatoid arthritis (RA) treated with biological or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs),…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].